Physician profile
Douglas Guenter
NPI 1659450989
$6,618.71
in general payments reported to CMS, 2019-2025
38 companies · $2,244 in 2025
The $2,244 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $138 · 2022: $334 · 2023: $1,503 · 2024: $1,784 · 2025: $2,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,519 · Education: $11.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,519.33 |
| Education | $11.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $938.89 | 2019-2025 | |
| Glaxosmithkline, LLC. | $658.15 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $649.04 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $498.70 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbott Laboratories | $435.20 | 2023-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $424.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $344.31 | 2019-2025 | Spiriva Respimat, Jardiance, Stiolto Respimat |
| Amgen INC. | $297.34 | 2019-2025 | Otezla, Repatha, Otezla |
| Exact Sciences Corporation | $279.71 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $270.85 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.04 | 2020-2025 | Xifaxan, Trulance |
| Corcept Therapeutics | $150.54 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $150.26 | 2023-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $146.97 | 2024-2025 | Voquezna |
| Alk-Abello, INC | $141.38 | 2025 | Grastek, Odactra, Ragwitek |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Guenter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.